Research summaries for everyoneNot medical advice
Sermorelin research reference vial, Elevated Pharma

Research reference · Hormones

Sermorelin

Sermorelin is a synthetic 29-residue analog of the active end of growth-hormone-releasing hormone, GHRH(1-29). It was previously marketed in the U.S. as Geref.

Published by Elevated Pharma ·

HormonesHuman research literature

Identity

What is Sermorelin?

GHRH(1-29)-NH2; the acetate salt needs its own documentation.

Research context

What has Sermorelin been studied for?

Human endocrine studies used GHRH(1-29) to test pituitary growth-hormone response; recent literature focuses on detection methods and sports use.

Evidence boundary

What does the research not show?

A base-compound record does not establish acetate content, purity or potency of a specific material.

U.S. status · November 7, 2026

Is Sermorelin FDA-approved?

No current FDA-approved sermorelin product is marketed. It was not on FDA’s 2026 compounding advisory agendas.

Key studies

The main Sermorelin research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 199 PubMed records for Sermorelin · Counts and selections checked November 7, 2026.

Reference identifiers

Sermorelin identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
Sermorelin
Also indexed as
Sermorelin acetate / GHRH(1-29) analog
Molecular formula
C149H246N44O42S
Molecular mass
3357.9 g/mol
PubChem CID
16132413

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.